Axsome Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales.

Axsome Therapeutics reported a Q3 loss of 94 cents per share, wider than expected, but total revenues surged 63% YoY to $171 million, beating estimates. The increase in revenues was attributed to strong sales of Auvelity. Net product revenues were $169.8 million, with Auvelity sales reaching $136.1 million, up 69% YoY. Sunosi's sales were $32.8 million, up 35% YoY.